Compare ORGN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGN | ADAG |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.4M | 146.3M |
| IPO Year | N/A | 2020 |
| Metric | ORGN | ADAG |
|---|---|---|
| Price | $0.12 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.4M | 198.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.18 | $3,688.61 |
| Revenue Next Year | $144.81 | $17.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $1.33 |
| 52 Week High | $0.95 | $4.58 |
| Indicator | ORGN | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 72.46 |
| Support Level | N/A | $1.69 |
| Resistance Level | $0.18 | N/A |
| Average True Range (ATR) | 0.02 | 0.41 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 13.55 | 77.26 |
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.